Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|January 27, 2023
Supplements and Featured Publications
- Cost-Effectiveness Analysis of CAB-LA for PrEP in the United States
Cost-Effectiveness Analysis of CAB-LA for PrEP in the United States
Advertisement
This content is paid for and developed by ViiV Healthcare.
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022 conference on May 10, 2022, in Washington, DC, Ashley E. Davis, PhD, director of health economics at RTI Health Solutions, presented the findings from a cost-effectiveness analysis of cabotegravir long-acting for PrEP in the United States, where it was 1 of 3 winners from more than 1600 submissions for “Best General Podium Research Presentation”. RTI Health Solutions received funding for this study from ViiV Healthcare. ViiV Healthcare sponsored the development of the model. This article summarizes the presentation highlights and was not peer reviewed.
Davis AE, Brogan AJ, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness analysis of CAB-LA for PrEP in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022; Washington, DC.
INTENDED FOR DISTRIBUTION ONLY TO PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES FOR HEALTHCARE ECONOMIC ANALYSIS PURSUANT TO SECTION 114 OF THE FOOD AND DRUG MODERNIZATION ACT TO FACILITATE DRUG SELECTION, ON A POPULATION BASIS, FOR COVERAGE OR REIMBURSEMENT.
Advertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
5